Skip to content

Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin

Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06086652
Enrollment
50
Registered
2023-10-17
Start date
2023-09-15
Completion date
2023-12-31
Last updated
2023-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastasis of Unknown Origin

Brief summary

In most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. However, Metastatic cancer of unknown primary site (MUO) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. Most common metastatic sites include the liver, lymph nodes, lungs, and bones. 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.

Interventions

DIAGNOSTIC_TESTPET/CT

detection of possible primary tumor

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Age \> 18 years Patients with metastatic tumor. Primary site was not detected with other radiological examinations Both male and female.

Exclusion criteria

Patients with known primary tumor Pregnancy. Age \< 18 years.

Design outcomes

Primary

MeasureTime frameDescription
primary tumor for metastasis of unknown originone monthprimary tumor for metastasis of unknown origin

Countries

Egypt

Contacts

Primary ContactDoaa I Mohamed, lecturer
doaaibrahim@med.soh.edu.eg01007779485

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026